luminal subtype
Recently Published Documents


TOTAL DOCUMENTS

55
(FIVE YEARS 21)

H-INDEX

11
(FIVE YEARS 2)

2022 ◽  
Vol 23 (2) ◽  
Author(s):  
Cheukfai Li ◽  
Guochun Zhang ◽  
Yulei Wang ◽  
Bo Chen ◽  
Kai Li ◽  
...  

2021 ◽  
Vol 8 (11) ◽  
pp. 191-197
Author(s):  
Jefri Adi Kam Sitepu ◽  
Marjono Dwi Wibowo ◽  
Iskandar Ali

Background: Breast cancer is the leading cause of cancer death in women worldwide. Breast cancer has been classified into several molecular subgroups with different prognostic consequences based on immunohistochemistry and molecular pathology. The prognosis that commonly used is 5-years survival. In this study we aimed to examine the relationship between luminal subtype and 5-year survival rate in patients with early post-mastectomy breast cancer. Methods: We recruited early breast cancer patient who underwent modified radical mastectomy (MRM) in Dr. Soetomo General Hospital (Surabaya, Indonesia) between 2010 – 2014. Breast cancer tissues were collected during surgery for immunohistochemistry. The patients’ 5-years survival data was obtained from medical records and by phone call to the patients or to the close relatives of the patients. Breast cancer subtype was determined based on the result of immunohistochemistry Results: A total of 84 patients was included in this study. The majority of patients were aged >40 years (72/84; 85.7%). There were 39 patients (39/84; 46.4%) with luminal A subtype and 45 patients (45/84; 53.6%) with luminal B subtype. Seventy-four patients were diagnosed as invasive ductal carcinoma histologically. Almost all of the patients were able to survive within 5 years (81/84; 96.4%). We found that luminal B had a 1.071 times higher risk of dying within 5 years after therapy than luminal type A, although the analysis did not show significant results (P = 0.101). Conclusion: Luminal B was the most prevalent breast cancer subtype in Surabaya, Indonesia. The prevalence of breast cancer was higher in patients aged >40 years. There was no significant difference between the 5-years survival of luminal A and luminal B subtypes. Keywords: survival, locally advanced breast cancer, luminal subtype, mastectomy.


2021 ◽  
pp. 103092
Author(s):  
Alfiah Amiruddin ◽  
Muhammad Nassrum Massi ◽  
Andi Asadul Islam ◽  
Ilhamjaya Patellongi ◽  
Muhammad Yogi Pratama ◽  
...  

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Sepideh Mehrpour Layeghi ◽  
Maedeh Arabpour ◽  
Abbas Shakoori ◽  
Mohammad Mehdi Naghizadeh ◽  
Yaser Mansoori ◽  
...  

Abstract Background Luminal breast cancer (BC) is the most frequent subtype accounting for more than 70% of BC. LncRNAs, a class of non-coding RNAs with more than 200 nucleotides, are involved in a variety of cellular processes and biological functions. Abberant expression is related to the development of various cancers, such as breast cancer. LINC01133, ZEB1-AS1, and ABHD11-AS1 were reported to be dysregulated in different cancers. However, their expression level in luminal BC remains poorly known. The aim of the present study was to evaluate the potential roles of these lncRNAs in BC, especially in luminal subtypes. Methods A comprehensive analysis was performed using the Lnc2Cancer database to identify novel cancer-associated lncRNA candidates. After conducting a literature review, three novel lncRNAs named LINC01133, ZEB1-AS1, and ABHD11-AS1 were chosen as target genes of the present study. Quantitative real‐time polymerase chain reaction (qRT-PCR) was used to evaluate the expression level of the mentioned lncRNAs in both luminal BC tissues and cell lines. Then, the correlation of the three mentioned lncRNAs expression with clinicopathological characteristics of the patients was studied. Moreover, several datasets were used to discover the potential roles and functions of LINC01133, ZEB1-AS1 and ABHD11-AS1 in luminal subtype of BC. Results According to the qRT-PCR assay, the expression levels of LINC01133 and ZEB1-AS1 were decreased in luminal BC tissues and cell lines. On the other hand, ABHD11-AS1 was upregulated in the above-mentioned samples. The expression levels of LINC01133, ZEB1-AS1, and ABHD11-AS1 were not associated with any of the clinical features. Also, the results obtained from the bioinformatics analyses were consistent with qRT-PCR data. Functional annotation of the co-expressed genes with the target lncRNAs, protein–protein interactions and significantly enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways across luminal BC were also obtained using bioinformatics analysis. Conclusions Taken together, our findings disclosed the dysregulation of LINC01133, ZEB1-AS1, and ABHD11-AS1 in luminal BC. It was revealed that LINC01133 and ZEB1-AS1 expression was significantly downregulated in luminal BC tissues and cell lines, while ABHD11-AS1 was upregulated considerably in the mentioned tissues and cell lines. Also, bioinformatics and systems biology analyses have helped to identify the possible role of these lncRNAs in luminal BC. However, further analysis is needed to confirm the current findings.


2021 ◽  
Vol 23 (2) ◽  
pp. 275-279
Author(s):  
Denis A. Ryabchikov ◽  
Svetlana V. Chulkova ◽  
Farhad A. Shamilov ◽  
Nail V. Chanturia ◽  
Sergey D. Zheltikov ◽  
...  

Background. The applying of immunotherapeutic approaches in cancer treatment requires a deep and comprehensive understanding of the tumor biological characteristics. In this regard, the study of the tumor immunophenotype is one of the leading scientific directions. The major histocompatibility complex molecules are considered to be the promising markers of the immunotherapy effectiveness prediciton. Aim. To research tumor immunophenotype in different molecular subtypes of breast cancer (BC). Materials and methods. The study included 99 patients with BC. Luminal cancer 84.8% (n=83), Erb-B2 overexpressing (HER2+) subtype 5.0% of cases (n=5), triple-negative BC 10.2% (n=10). Stages: T1 (51.5%), T2 (44.4%), T3 (2.0%). Lymph node metastases (N+) were present in 39.4% (n=39) of cases. Grade of malignancy: 80.8% (G2). Samples of tumor tissue and bone marrow were examined. Immunophenotyping of the tumor was carried out on cryostat sections by the method of immunofluorescense. Antibodies to HLA-I, HLA-DR, CD71 were used and were directly conjugated to fluorochromes PE, FITC, PE-Cy5. The bone marrow was examined by a morphological method using light microscopy. Statistical data processing was performed using the IBM-SPSS statistics v2.1. Results. In 50.8% (31/61) cases of luminal BC (LBC), the HLA-I molecule is absent on the membrane or is expressed by single tumor cells. A decrease in HLA-I expression levels in the luminal subtype was combined with the absence of HLA-DR antigens, which was found in 63.1% of cases. A higher frequency of HLA-I expression is observed in the Erb-B2 overexpressing BC, the differences are insignificant. Expression of CD71 was defected in 67.8% (40/59) of the studied samples of LBC. CD71 was expressed on the surface of most tumor cells (70%) in triple-negative BC. There were no statistically significant differences between the studied molecular subtypes of BC. Analysis of the luminal subtypes revealed that CD71 expression was observed much more often in luminal B subtype: 76.5% (n=26) and 75% (n=3) versus 52.4% (n=11). HLA-I expressing luminal cancer were characterized by higher levels of erythroid precursors (polychromatophilic normoblasts 9.00.9 and 5.80.8%, p=0.0017; oxyphilic normoblasts (7.90.7 and 5.30.6%, p=0.008), an increase in the amount of erythroid germ cells (17.71.5 and 11.61.5%, р=0.009) and an increased content of myelokaryocytes (93.117.1 thousand/l versus 57.39.0 thousand/l, p=0.083). Conclusion. In LBC a decrease in the expression levels of HLA-I class molecules was noted in combination with the absence of HLA-DR antigens on the membrane of tumor cells, which was observed in more than half of the analyzed samples. The frequency of expression in triple-negative cancer is higher than in the luminal subtype. There were no statistically significant differences between molecular subtypes by the level of expression of HLA-I and II class molecules. Transferrin receptor expression has been reported in most cases of triple-negative BC subtype. The interconnection between the expression of HLA-I histocompatibility molecules and hematopoetic parameters in LBC has been established.


2021 ◽  
Author(s):  
Tiffany Tate ◽  
Tina Xiang ◽  
Mi Zhou ◽  
William Y. Kim ◽  
Xiao Chen ◽  
...  

AbstractPparg, a nuclear receptor, is downregulated in basal subtype bladder cancers that tend to be muscle invasive and amplified in luminal subtype bladder cancers that tend to be non-muscle invasive. Bladder cancers derive from the urothelium, one of the most quiescent epithelia in the body which is composed of basal, intermediate, and superficial cells. We find that expression of an activated form of Pparg (VP16;Pparg) in basal progenitors induces formation of superficial cells in situ, that exit the cell cycle, and do not form tumors. Expression in basal progenitors that have been activated by mild injury however, results in luminal tumor formation. We find that tumors are immune deserted, which may be linked to downregulation of Nf-kb, a Pparg target. Interestingly, some luminal tumors begin to shift to basal subtype tumors with time, downregulating Pparg and other luminal markers. Our findings have important implications for treatment and diagnosis bladder cancer.


Author(s):  
Xin Ding ◽  
Ya Li ◽  
Jinhui Lü ◽  
Qian Zhao ◽  
Yuefan Guo ◽  
...  

Cancer stem cells (CSCs) are believed to be the main source of cancer relapse and metastasis. PIWI-interacting small non-coding RNAs (piRNAs) have been recently recognized to be relevant to cancer biology. Whether and how piRNAs regulate human CSCs remain unknown. Herein, upregulation of piR-823 was identified in tested luminal breast cancer cells, especially in the luminal subtype of breast CSCs. Enforced expression or targeted knockdown of piR-823 demonstrated its oncogenic function in regulating cell proliferation and colony formation in MCF-7 and T-47D breast cancer cells. In addition, piR-823 induced ALDH (+) breast CSC subpopulation promoted the expression of stem cell markers including OCT4, SOX2, KLF4, NANOG, and hTERT, and increased mammosphere formation. Tail vein injection of magnetic nanoparticles carrying anti-piR-823 into the mammary gland of tumor-burdened mice significantly inhibited tumor growth in vivo. DNA methyltransferases (DNMTs) including DNMT1, DNMT3A, and DNMT3B were demonstrated to be the downstream genes of piR-823, which regulate gene expression by maintaining DNA methylation. piR-823 increased the expression of DNMTs, promoted DNA methylation of gene adenomatous polyposis coli (APC), thereby activating Wnt signaling and inducing cancer cell stemness in the luminal subtype of breast cancer cells. The current study not only revealed a novel mechanism through which piRNAs contribute to tumorigenesis in breast cancer by regulating CSCs, but also provided a therapeutic strategy using non-coding genomes in the suppression of human breast cancer.


2021 ◽  
Vol 10 ◽  
Author(s):  
Lin Yang ◽  
Shuangling Wu ◽  
Chunhui Ma ◽  
Shuhui Song ◽  
Feng Jin ◽  
...  

RNA N6-methyladenosine (m6A) methylation is the most prevalent epitranscriptomic modification in mammals, with a complex and fine-tuning regulatory system. Recent studies have illuminated the potential of m6A regulators in clinical applications including diagnosis, therapeutics, and prognosis. Based on six datasets of breast cancer in The Cancer Genome Atlas (TCGA) database and two additional proteomic datasets, we provide a comprehensive view of all the known m6A regulators in their gene expression, copy number variations (CNVs), DNA methylation status, and protein levels in breast tumors and their association with prognosis. Among four breast cancer subtypes, basal-like subtype exhibits distinct expression and genomic alteration in m6A regulators from other subtypes. Accordingly, four representative regulators (IGF2BP2, IGF2BP3, YTHDC2, and RBM15) are identified as basal-like subtype-featured genes. Notably, luminal A/B samples are subclassified into two clusters based on the methylation status of those four genes. In line with its similarity to basal-like subtype, cluster1 shows upregulation in immune-related genes and cell adhesion molecules, as well as an increased number of tumor-infiltrating lymphocytes. Besides, cluster1 has worse disease-free and progression-free survival, especially among patients diagnosed with stage II and luminal B subtype. Together, this study highlights the potential functions of m6A regulators in the occurrence and malignancy progression of breast cancer. Given the heterogeneity within luminal subtype and high risk of recurrence and metastasis in a portion of patients, the prognostic stratification of luminal A/B subtypes utilizing basal-featured m6A regulators may help to improve the accuracy of diagnosis and therapeutics of breast cancer.


2021 ◽  
Vol 10 ◽  
Author(s):  
Wen-jie Tang ◽  
Zhe Jin ◽  
Yan-ling Zhang ◽  
Yun-shi Liang ◽  
Zi-xuan Cheng ◽  
...  

PurposeTo assess whether apparent diffusion coefficient (ADC) metrics can be used to assess tumor-infiltrating lymphocyte (TIL) levels in breast cancer, particularly in the molecular subtypes of breast cancer.MethodsIn total, 114 patients with breast cancer met the inclusion criteria (mean age: 52 years; range: 29–85 years) and underwent multi-parametric breast magnetic resonance imaging (MRI). The patients were imaged by diffusion-weighted (DW)-MRI (1.5 T) using a single-shot spin-echo echo-planar imaging sequence. Two readers independently drew a region of interest (ROI) on the ADC maps of the whole tumor. The mean ADC and histogram parameters (10th, 25th, 50th, 75th, and 90th percentiles of ADC, skewness, entropy, and kurtosis) were used as features to analyze associations with the TIL levels in breast cancer. Additionally, the correlation between the ADC values and Ki-67 expression were analyzed. Continuous variables were compared with Student’s t-test or Mann-Whitney U test if the variables were not normally distributed. Categorical variables were compared using Pearson’s chi-square test or Fisher’s exact test. Associations between TIL levels and imaging features were evaluated by the Mann-Whitney U and Kruskal-Wallis tests.ResultsA statistically significant difference existed in the 10th and 25th percentile ADC values between the low and high TIL groups in breast cancer (P=0.012 and 0.027). For the luminal subtype of breast cancer, the 10th percentile ADC value was significantly lower in the low TIL group (P=0.041); for the non-luminal subtype of breast cancer, the kurtosis was significantly lower in the low TIL group (P=0.023). The Ki-67 index showed statistical significance for evaluating the TIL levels in breast cancer (P=0.007). Additionally, the skewness was significantly higher for samples with high Ki-67 levels in breast cancer (P=0.029).ConclusionsOur findings suggest that whole-lesion ADC histogram parameters can be used as surrogate biomarkers to evaluate TIL levels in molecular subtypes of breast cancer.


Sign in / Sign up

Export Citation Format

Share Document